TOXICOLOGICAL AND HYGIENIC ASSESSMENT OF AN ALTERNATIVE METHOD OF IQOS TOBACCO USING
Keywords:
smoking, IQOS, cigarettes, toxicity, tobacco smoke, aerosol.Abstract
Abstract. According to objective experimental studies, the use of IQOS causes endothelial dysfunction. The rapid adverse vascular effects for IQOS are similar to those for ordinary cigarette smoking. Assessment of the chemical composition of the aerosol and some studies indicate the possibility of IQOS to cause some diseases that did not occur during regular cigarettes smoking, including liver damage. Preliminary tests initiated by the manufacturer show that IQOS systems might be the best alternative for heavy smokers who have failed to provide comprehensive treatment for nicotine addiction. Independent research suggests that the benefits of IQOS over traditional cigarette smoking are contradictory. The additional clinical observations are needed for the determination of the short term and long term health effects of using heated not burned tobacco products.
References
IQOS official site [online] Iqos.com.ua. Available at: <https://www.iqos.com.ua/uk/newslist/iqos-countries> (accessed 07.12.2021).
Fried, N. and Gardner, J., 2020. Heat-not-burn tobacco products: an emerging threat to cardiovascular health. American Journal of Physiology-Heart and Circulatory Physiology, 319(6), pp.H1234-H1239. doi: 10.1152/ajpheart.00708.2020.
Sutanto, E., Miller, C., Smith, D., O'Connor, R., Gravely, S., Hammond, D., Hyland, A., Cummings, K., Quah, A., Fong, G., Agar, T. and Goniewicz, M., 2020. Perceived relative harm of heated tobacco products (IQOS),e-cigarettes, and cigarettes among adults in Canada: Findingsfrom the ITC Project. Tobacco Induced Diseases, 18(September), pp.1-5. doi: 10.18332/tid/127233.
Center for Tobacco Products. Addendum to FDA Briefing Document. January 24-25, 2018. Meeting of the Tobacco Products Scientific Advisory Committee (TPSAC). 2018. Fda.gov. 2021. [online] Available at: <https://www.fda.gov/media/110668/download> (accessed 07.12.2021).
St.Helen, G., Jacob III, P., Nardone, N. and Benowitz, N., 2018. IQOS: examination of Philip Morris International’s claim of reduced exposure. Tobacco Control, 27(Suppl 1), pp.s30-s36. https://doi.org/10.1136/tobaccocontrol-2018-054321
BAŞARAN, R., GÜVEN, N. and EKE, B., 2019. An Overview of iQOS® as a New Heat-Not- Burn Tobacco Product and Its Potential Effects on Human Health and the Environment. Turkish Journal of Pharmaceutical Sciences, 16(3), pp.371-374. doi: 10.4274/tjps.galenos.2018.79095.
Nabavizadeh, P., Liu, J., Havel, C., Ibrahim, S., Derakhshandeh, R., Jacob III, P. and Springer, M., 2018. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. Tobacco Control, 27(Suppl 1), pp.s13-s19. doi:
1136/tobaccocontrol-2018-054325.
Lopez, A., Hiler, M., Maloney, S., Eissenberg, T. and Breland, A., 2016. Expanding clinical laboratory tobacco product evaluation methods to loose-leaf tobacco vaporizers. Drug and Alcohol Dependence, 169, pp.33-40. doi: 10.1016/j.drugalcdep.2016.10.005
Poussin, C., Laurent, A., Peitsch, M., Hoeng, J. and De Leon, H., 2016. Systems toxicologybased assessment of the candidate modified risk tobacco product THS2.2 for the adhesion of monocytic cells to human coronary arterial endothelial cells. Toxicology, 339, pp.73-86. doi:
1016/j.tox.2015.11.007
Van der Toorn, M., Frentzel, S., De Leon, H., Goedertier, D., Peitsch, M. and Hoeng, J., 2015. Aerosol from a candidate modified risk tobacco product has reduced effects on chemotaxis and transendothelial migration compared to combustion of conventional cigarettes. Food and Chemical Toxicology, 86, pp.81-87. doi: 10.1016/j.fct.2015.09.016
Znyk, M., Jurewicz, J. and Kaleta, D., 2021. Exposure to Heated Tobacco Products and Adverse Health Effects, a Systematic Review. International Journal of Environmental Research and Public Health, 18(12), p.6651. doi: 10.3390/ijerph18126651.
Leigh, N., Palumbo, M., Marino, A., O’Connor, R. and Goniewicz, M., 2018. Tobaccospecific nitrosamines (TSNA) in heated tobacco product IQOS. Tobacco Control, 27(Suppl 1), pp.s37-s38. doi: 10.1136/tobaccocontrol-2018-054318
Chun, L., Moazed, F., Matthay, M., Calfee, C. and Gotts, J., 2018. Possible hepatotoxicity of IQOS. Tobacco Control, 27(Suppl 1), pp.s39-s40. doi: 10.1136/tobaccocontrol-2018-054320
Baker G, Picavet P, Smiith M, et al. , (2018), Summary of Evidence on the Absence of Hepatotoxicity of IQOS: Response to the Article Entitled “Possible Hepatotoxicity of IQOS” by Chun Et Al., 2018 (PMI Science) [online] Available at <https://www.pmiscience.com/discover/news/summary-of-evidence-on-the-absence-ofhepatotoxicity-
of-iqos-response> (accessed 07.12.2021).
Glantz, S., 2018. Heated tobacco products: the example of IQOS. Tobacco Control, 27(Suppl 1), pp.s1-s6. doi: 10.1136/tobaccocontrol-2018-054601.
Horinouchi, T. and Miwa, S., 2021. Comparison of cytotoxicity of cigarette smoke extract derived from heat-not-burn and combustion cigarettes in human vascular endothelial cells. Journal of Pharmacological Sciences, 147(3), pp.223-233. doi: 10.1016/j.jphs.2021.07.005.
Moazed, F., Chun, L., Matthay, M., Calfee, C. and Gotts, J., 2018. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS. Tobacco Control, 27(Suppl 1), pp.s20-s25. doi: 10.1136/tobaccocontrol-2018-054296.
